Oncology Venture - to participate and present at the Annual BioEurope Conference
Hoersholm, Denmark – November 3rd 2017 – Oncology Venture Sweden AB (OV:ST) announces that OV will participate and present at the 23rd Annual International Bio-Europe Partnering Conference, on November 6-8, in Berlin.
Chief Executive Officer, MD, PhD Peter Buhl Jensen, will present Oncology Venture at Bio-Europe, November 7th 2017 at 5:30pm CET, with a discussion period to follow. Furthermore, Peter Buhl Jensen will hold 1x1 meetings, joined by Chief Operating Officer, Ulla Hald Buhl, and Vice President, Business Development, Claus Deichgræber. Over 30 meetings are now scheduled.
Investors wishing to meet with Oncology Venture at or around the Bio-Europe Conference should notify the conference desk, or contact Claus Deichgræber to schedule a meeting.
The 23rd annual BIO-Europe is Europe’s largest partnering conference serving the global biotechnology industry, and with delegates from all parts of the value chain. This years Bio-Europe will draw over 4.000 delegates from over 60 countries representing more than 2.000 companies for the three days of high level networking.
For further information, please contact:
Ulla Hald Buhl, COO and
Chief IR & Communications
Mobile: +45 2170 1049
Peter Buhl Jensen, CEO
Mobile: +45 21 60 89 22
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has an exclusive license to use the Drug Response Predictor (DRP™) technology in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors’ genes are screened first with DRP™ and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for breast cancer in collaboration with Cadila Pharmaceuticals; Irofulven developed from a fungus for prostate cancer; and APO010 – an immuno-oncology product for multiple myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US-based company focusing on precision medicine for women’s cancers with a pipeline of three promising Phase 2 product candidates, and Danish OV-SPV 2 which will test and potentially develop the Novartis small molecule kinase inhibitor. Oncology Venture currently owns 92% of 2X Oncology Inc. and 40% of OV-SPV2 ApS.